维格列汀联合二甲双胍治疗老年2型糖尿病对糖脂代谢及血清TNF-α、hs-CRP及IL-8的影响

Effects of Vildagliptin Combined with Metformin on Glucose-Lipid Metabolism, Serum TNF-α,hs-CRP and IL-8 in Elderly Patients with Type 2 Diabetes Mellitus

目的 探讨维格列汀联合二甲双胍治疗老年2型糖尿病(T2MD)患者的疗效。方法 选取2019年12月至2020年1月本院收治的104例老年T2MD患者,随机分为对照组和治疗组,每组52例。对照组予以二甲双胍治疗;治疗组予以维格列汀+二甲双胍治疗。比较治疗前后两组患者的血糖水平[空腹血糖(FBG)、餐后2 h血糖(2hBG)、糖化血红蛋白(HbA1c)]、血脂水平[血脂(TC)、甘油三脂(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]、炎症指标[肿瘤坏死因子-α(TNF-α)、超敏C-反应蛋白(hs-CRP)、白细胞介素-8(IL-8)]及治疗期间的不良反应发生情况。结果 治疗后,两组患者FBG、2 h PG、HbA1c、TC、TG、LDL-C、TNF-α、hs-CRP、IL-8水平均低于治疗前,HDL-C水平高于治疗前(P<0.05),且治疗组FBG、2hPG、HbA1c、TC、TG、LDL-C、TNF-α、hs-CRP、IL-8水平均低于对照组,HDL-C水平高于对照组(P<0.05);治疗期间,两组不良反应总发生率无明显差异(P>0.05)。结论 维格列汀联合二甲双胍能有效降低老年T2MD患者糖脂水平,减少炎症反应,安全性高。

Objective To explore the actual curative effect of vildagliptin combined with metformin on elderly patients with type 2 diabetes mellitus(T2MD).Methods A total of 104 elderly patients with T2MD admitted to the hospital were enrolled between December 2019 and January 2020. They were randomly divided into control group and treatment group, 52 cases in each group. The control group was treated with metformin, while treatment group was treated with vildagliptin and metformin. The levels of blood glucose[fasting blood glucose(FBG),postprandial 2 h blood glucose(2 h BG),hemoglobin A1c(HbA1c)], blood lipid[total cholesterol(TC),triglyceride(TG),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C)]and inflammation indexes[tumor necrosis factor-α(TNF-α),high-sensitivity C-reactive protein(hs-CRP),interleukin-8(IL-8)]before and after treatment, and adverse reactions during treatment between the two groups were compared.Results After treatment, levels of FBG,2 h PG,HbA1c, TC, TG,LDL-C, TNF-α,hs-CRP and IL-8 were decreased, while HDL-C level was increased in both groups(P<0.05).The levels of FBG,2hPG,HbA1c, TC, TG, LDL-C,TNF-α,hs-CRP and IL-8 in treatment group were lower than those in control group, while HDL-C level was higher than that in control group(P<0.05).During treatment, there was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Vidagliptin combined with metformin can effectively reduce glucose-lipid level and inflammation response in elderly patients with T2MD, with high safety.